Review
Copyright ©The Author(s) 2015.
World J Hepatol. Apr 8, 2015; 7(4): 673-687
Published online Apr 8, 2015. doi: 10.4254/wjh.v7.i4.673
Table 1 Phase III trials of some systemic targeted agents in advanced hepatocellular carcinoma
Ref.Study designPatients, nOverall survival, mo
Zhu et al[109] (SEARCH trial)Sorafenib vs sorafenib + erlotinib358 vs 362Sorafenib: 8.5 Sorafenib + erlotinib: 9.5
Cheng et al[105] (SUN1170 trial)Sorafenib vs sunitinib544 vs 530Sorafenib: 10.2 Sunitinib: 7.9
Cainap et al[106] (LIGHT trial)Sorafenib vs linifanib517 vs 518Sorafenib: 9.8 Linifanib: 9.1
Johnson et al[107] (BRISK-FL trial)Sorafenib vs brivanib578 vs 577Sorafenib: 9.9 Brivanib: 9.5
Llovet et al[108] (BRISK-PS trial)Brivanib vs placebo263 vs 132Brivanib: 9.4 Placebo: 8.3